7 Jan 2014 16:54
8 January 2014
Akers Biosciences, Inc.
("ABI" or the "Company")
SEC filings available on Company's web site
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that, further to its previous announcements regarding the proposed listing of the Company's common shares (the "Securities") on The NASDAQ Capital Market ("NASDAQ") and the concurrent registered public offering (the "Offering"), all the amendments to the Company's S-1 filing are available on the Company's web site (at http://ir.akersbiosciences.com/sec.cfm) together with the Free Writing Prospectus (FWP), or presentation, which has been filed with the SEC and will be used during the marketing process.
The Offering is subject to market and other conditions, and there can be no assurances as to whether or when the Offering may be completed or as to the actual size or terms of the Offering. A registration statement relating to these Securities has been filed with the SEC but has not yet become effective. These Securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these Securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the Securities laws of any such state or jurisdiction.
- ends -
Enquiries:
Thomas A. Nicolette, President and CEO | Tel. +1 856 848 8698 |
Antony Legge / James Thomas Daniel Stewart (Nomad and Broker)
| Tel. +44 (0)20 7776 6550 |
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com
About Chubeworkx / en10 Global Limited
Combining leading science innovations and clever design, en10, an indirect subsidiary of Chubeworkx, provides people the means to effect simple, precise, low-cost alcohol screening and programmes and products to encourage broader, positive changes in attitudes to responsible alcohol consumption. It provides a fresh approach to achieving a healthy work culture and a more productive business: cutting costs and improving lives. Additional information on the company and its products can be found at www.en-10.com